Informations sur le produit
- TKI258 Dilactic acid
- 2-Hydroxypropanoic acid compd. with 4-amino-5-fluoro-3-[6-(4-methyl-1-piperazinyl)-1H-benzimidazol-2-yl]-2(1H)-quinolinone
Dovitinib is a tyrosine kinase inhibitor that blocks the growth of cancer cells by inhibiting the activation of their protein kinases. It has been shown to be effective in the treatment of leukemic stem cells and various types of cancer, including activated T-cells, breast cancer, and gastrointestinal cancer. Dovitinib also inhibits bone growth, leading to bone lesions and decreased bone mineral density. In animals with a v600 mutation in their KIT gene, dovitinib was found to be an effective agent for treating these cancers. This drug also modulates the activity of various growth factors such as platelet-derived growth factor (PDGF) and transforming growth factor beta (TGF-β). Dovitinib has been shown to have good efficacy at low doses, with no significant dose-limiting toxicity observed up to 100 mg/day.
Dovitinib can be taken orally or intravenously in a dose of 10
